GH director reports RSU conversion of 154 shares; 18,436 owned

Rhea-AI Filing Summary

Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.

The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.

Insider Trade Summary

154 shares exercised/converted

Mixed 2 txns

Insider Krognes Steve E.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	154	$0.00	--
Exercise	Common Stock	154	$0.00	--

Holdings After Transaction: Restricted Stock Units — 1,235 shares (Direct); Common Stock — 18,436 shares (Direct)

Footnotes (1)

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. Not applicable for Restricted Stock Units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/31/2025		M		154	A	$0	18,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/31/2025		M			154	(1)	(2)	Common Stock	154	$0	1,235	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) report in this Form 4?

A director reported the conversion of restricted stock units into 154 common shares on 10/31/2025 at a price of $0 (code M).

How many Guardant Health (GH) shares does the reporting person hold after the transaction?

He directly beneficially owned 18,436 common shares after the reported transaction.

How many RSUs remain outstanding for the reporting person?

He reported 1,235 RSUs beneficially owned as derivative securities following the transaction.

What is the vesting schedule of the RSU grant?

Granted on August 9, 2022: 25% vested on June 30, 2023; the remaining 75% vests in substantially equal monthly installments over three years thereafter.

What is the reporting person’s relationship to Guardant Health (GH)?

He is a Director.

Was the Form 4 filed by one or multiple reporting persons?

It was filed by one reporting person.